Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Bosley Revitalizer 96 Laser Cap is indicated to treat Androgenic Alopecia and promote hair growth in males who have Norwood-Hamilton Classifications of Ila to V patterns of hair loss and to treat Androgenic Alopecia and promote hair growth in females who have Ludwig (Savin) Scale I-1 to I-4, II-1, II-2, or frontal; both with Fitzpatrick Skin Types I to IV.

    Device Description

    The Bosley Revitalizer 96 Laser Cap consists of 96 red, visible light, diode lasers operating at 650 nanometers, configured within an outer helmet and protective inner liner, and configured for portable use with rechargeable battery and adapter. Just as with the Bosley Revitalizer 272 and 164 Laser Caps, the 96 Laser Cap system can detect whether or not the device is in the correct position on the user's head and will automatically pause therapy if it is not. The device will resume therapy when the correct head position is re-established. The system is powered by rechargeable Lithium-ion battery cells assembled into a proprietary battery pack. Both the battery pack and charger are fully compliant with recognized, international standards.

    AI/ML Overview

    The provided text is a 510(k) Premarket Notification summary for the Bosley Revitalizer 96 Laser Cap. Based on the document, this is a Special 510(k) submission, meaning the device is a modification of a previously cleared device. Therefore, a new, independent clinical study to prove efficacy and safety against new acceptance criteria was not performed. Instead, the submission relies on the substantial equivalence to predicate devices and verification/validation activities to confirm that the modifications do not introduce new risks or significantly alter performance compared to the original design.

    Here's an analysis of the requested information based on the provided text:

    1. A table of acceptance criteria and the reported device performance

    The document doesn't explicitly state numerical acceptance criteria for a new clinical study. Instead, it relies on the safety and efficacy of its predicate devices. The "performance" assessment is primarily focused on confirming that the modified device (with fewer diodes) still meets established safety standards and that its reduced "dose" is acceptable given the intended indefinite use and lower cost.

    Acceptance Criteria (Implied)Reported Device Performance
    Compliance with recognized safety standards (e.g., IEC-60601-1)Conforms to IEC-60601-1, IEC-60601-11, IEC-60601-2-22 (2007/Third Ed.), and IEC60825-1 (Ed. 3). Charger conforms to IEC 61959.
    Laser class of 3R, AEL max 5 mW per diodeLaser class 3R, individual diode output ≤ 5mW.
    Laser wavelength, output power (per diode), output beam, energy type, laser field, treatment area remain the same as predicate.Exactly the same laser wavelength (650 nm), output power (per diode), output beam, energy type, laser field, and treatment area as the Bosley Revitalizer 272 and 164 Laser Caps.
    No new unacceptable risks due to reduced number of laser diodesRisk analysis (FMEA) concluded no new unacceptable risk due to reduced number of laser diodes.
    Functionality operates as designedAll functions of the modified product have been verified to operate as designed, and all acceptance criteria (for functional verification) were met.
    Acceptable efficacy given reduced dose"Modestly lower efficacy is accepted by users, with the understanding that treatment is intended to be continued indefinitely." Believed that reduced number of laser diodes will only affect the time required to witness the same result.
    No reported adverse eventsNo reported adverse events for these products (Bosley Revitalizer 272 and 164 Laser Caps, and reference devices).

    2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)

    No new clinical study was conducted for this Special 510(k) submission. The performance assessment relied on verification and validation activities of the modified device and comparison to previously cleared predicate devices. Therefore, there is no "test set" in the context of a new clinical efficacy study, nor explicit sample size or data provenance from such a study.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)

    Not applicable, as no new clinical study requiring ground truth establishment was conducted for this Special 510(k) submission.

    4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

    Not applicable, as no new clinical study requiring adjudication was conducted for this Special 510(k) submission.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    Not applicable. The device is a laser cap for hair growth, not an AI-assisted diagnostic tool involving human readers.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    Not applicable. The device is a hardware device for hair growth, not an algorithm.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    Not applicable, as no new clinical study requiring ground truth was conducted for this Special 510(k) submission. The efficacy claims for the predicate devices would have been based on clinical trials measuring hair growth (e.g., hair count, global photographic assessment), but details of those specific ground truths are not provided in this document.

    8. The sample size for the training set

    Not applicable, as no new clinical study was conducted. No "training set" in the context of AI or a new clinical trial is mentioned.

    9. How the ground truth for the training set was established

    Not applicable, as no new clinical study was conducted.

    Ask a Question

    Ask a specific question about this device

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The BOSLEY Revitalizer 272 and 164 Laser Caps are indicated to treat Androgenic Alopecia and promote hair growth in males who have Norwood-Hamilton Classifications of Ila to V patterns of hair loss and to treat Androgenic Alopecia and promote hair growth in females who have Ludwig (Savin) Scale I-1 to I-4, II-1, II-3, or frontal; both with Fitzpatrick Skin Types I to IV.

    Device Description

    The BOSLEY Revitalizer 272 and 164 Laser Caps are low level laser therapy (LLLT) devices designed to promote hair growth in women and men by exposing the entire scalp to the photobiostimulation of 272 or 164 visible red light-emitting diodes at 650-nm and 5mW each. The lasers are contained inside a lightweight cap. The device is powered by an included battery pack and automatically turns off after 30 minutes.

    AI/ML Overview

    The provided text describes a 510(k) submission for the BOSLEY Revitalizer 272 and 164 Laser Caps. Here's a breakdown of the requested information:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria for the device were primarily related to OTC/Usability Testing and Biocompatibility.

    Acceptance Criteria CategorySpecific CriteriaReported Device Performance
    OTC/Usability Testing80% success rate in self-selection, comprehension of labeling and instructions, and usability. This includes accurate self-categorization of (a) skin type (I-IV) and (b) hair loss pattern (Norwood-Hamilton IIa-V for males, Ludwig (Savin) I-1 to I-4, II-1, II-3, or frontal for females), to determine candidacy for treatment or contraindication.95% overall of participants correctly judged themselves on hair loss candidacy. 100% of participants accurately categorized their skin type as suitable for treatment or not suitable when compared with physician ratings. 100% of women correctly identified their candidacy for treatment or incorrectly judged themselves unsuitable for treatment based on hair loss self-rating. 90% of men correctly identified their candidacy for treatment or incorrectly judged themselves unsuitable for treatment based on hair loss self-rating (3 males incorrectly identified themselves as treatment candidates).
    Biocompatibility- Material used in manufacturing must be non-cytotoxic. - Material must not be a sensitizer for skin contact.- Cytotoxicity tests demonstrated that the material used in the manufacturing of the caps is non-cytotoxic. The caps met the requirements of ISO 10993-1:2009, ISO 14971:2007, and FDA General Program Memorandum #G95-1, for surface devices with limited contact (<24 hours) with the skin and was considered safe for use. - Skin sensitization tests demonstrated that the material used in the manufacturing of the caps were not considered a sensitizer.
    Non-clinical Performance- Compliance to design specifications for all functions. - Operation as designed. - Meeting all acceptance criteria in performance testing.- All functions were verified to operate as designed. - The BOSLEY Revitalizer 272 and 164 Laser Caps met all acceptance criteria in the performance testing.
    Laser SafetyCertification to laser system classification 3R (same as predicate devices).- Testing to IEC 60825-1 certifies the laser system to classification 3R.
    Electrical Safety & EMCCompliance with IEC 60601-1:2012 3rd Edition, IEC 60601-1-2, and IEC 60601-1-11. Charger conforms to IEC 60950. Battery conforms to IEC 62133.- The BOSLEY Revitalizer 272 and 164 Laser Caps were tested and comply with Electrical Safety and EMC testing, including the requirements of IEC 60601-1:2012 3rd Edition, IEC 60601-1-2, and IEC 60601-1-11. - The charger conforms to IEC 60950 and the battery to IEC 62133.

    2. Sample size used for the test set and the data provenance

    • Sample Size for OTC/Usability Test Set: 30 female participants and 30 male participants (total of 60). One male was excluded, making the total male population in the analysis 29. So, the effective sample size for analysis was 59 (30 females, 29 males).
    • Data Provenance: The study was conducted in February 2018. The specific country of origin is not explicitly stated, but the submission is to the U.S. FDA, and a US address is provided for the "Premarket Submission Applicant Name/510k Holder." The nature of the study (observing participant comprehension and usability in a controlled setting) makes it a prospective study.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    • Number of Experts: One licensed physician.
    • Qualifications of Experts: The expert was described as a "licensed physician skilled in hair loss and skin clinical studies."

    4. Adjudication method for the test set

    • The text describes a process where participants self-evaluated their candidacy, and then a licensed physician rated their pictures for hair loss and skin type (ground truth). An independent blinded statistician was provided with this data. The "adjudication" in this context involved comparing the participant's self-assessment against the physician's assessment of hair loss and skin type. There wasn't an explicit 2+1 or 3+1 expert consensus method described for establishing the ground truth; rather, it was a single expert's assessment used as the reference.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No, an MRMC comparative effectiveness study was not done. This submission is for a Low-Level Laser Therapy (LLLT) device for hair growth, not an AI-assisted diagnostic or imaging device used by human readers. The study described focuses on usability and comprehension for over-the-counter use.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    • N/A. The device is a physical laser cap used by individuals, not a standalone algorithm. The "standalone performance" mentioned in the non-clinical testing section refers to the device's technical specifications and safety compliance (laser classification, electrical safety), not an AI algorithm's performance.

    7. The type of ground truth used

    • For the OTC/Usability study, the ground truth for participant candidacy (hair loss classification and skin type) was established by a licensed physician skilled in hair loss and skin clinical studies reviewing photos of the participants.

    8. The sample size for the training set

    • The document does not mention a training set or any machine learning/AI components. The non-clinical performance and usability studies described are for traditional medical device verification and validation.

    9. How the ground truth for the training set was established

    • N/A, as no training set for an AI/ML model was described.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1